Novartis has responded to the inclusion of its heart failure blockbuster Entresto on the list of the first 10 drugs that will be subject to Medicare pricing negotiations,
The identity of the first 10 medicines that will be subject to the first round of Medicare pricing negotiations has been revealed and, as expected, some big brands are in
The Centers for Medicare and Medicaid Services (CMS) has made some minor changes to its plan to allow Medicare to negotiate some drug prices after a series of lawsuits fro
The Centers for Medicare and Medicaid Services (CMS) in the US has provided more details about the controversial plan to require participation in a patient registry as a c
Legal challenges to Medicare’s price negotiation initiative introduced in the Inflation Reduction Act (IRA) continue to emerge, with pharmaceutical trade organisation PhRM